Retraction: Knockdown of NEAT1 restrained the malignant progression of glioma stem cells by activating microRNA let-7e (Oncotarget. (2016) 7 (62208–62223) DOI: 10.18632/oncotarget.11403);Knockdown of NEAT1 restrained the malignant progression of glioma stem cells by activating microRNA let-7e

Oncotarget

Volumn 7, Issue 38, 2016, Pages 62208-62223

  Gong, Wei ^a   Zheng, Jian ^a,b   Liu, Xiaobai ^a,b   Ma, Jun ^a   Liu, Yunhui ^a,b   Xue, Yixu ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Liaoning Clinical Medical Research Center in Nervous System Disease   (China)

Author keywords

Glioma stem cells; Let 7e; LncRNAs; NEAT1; NRAS

Indexed keywords

ARGONAUTE 2 PROTEIN; LONG UNTRANSLATED RNA; MICRORNA; MICRORNA LET 7E; NRAS PROTEIN; NUCLEAR PARASPECKLE ASSEMBLY TRANSCRIPT 1; ONCOPROTEIN; UNCLASSIFIED DRUG; ARGONAUTE PROTEIN; EIF2C2 PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; MIRNLET7 MICRORNA, HUMAN; NEAT1 LONG NON-CODING RNA, HUMAN; NRAS PROTEIN, HUMAN; SMALL INTERFERING RNA;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTE; BINDING SITE; CANCER INHIBITION; CANCER TISSUE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE SILENCING; GLIOMA CELL LINE; GLIOMA STEM CELL; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; MALE; MALIGNANT TRANSFORMATION; MOUSE; NEAT1 GENE; NONHUMAN; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECIPROCAL REPRESSION; TUMOR INVASION; UPREGULATION; ANIMAL; BRAIN; BRAIN TUMOR; CANCER STEM CELL; CARCINOGENESIS; CELL MOTION; DISEASE EXACERBATION; DRUG SCREENING; GENE KNOCKDOWN; GENETICS; GLIOBLASTOMA; HEK293 CELL LINE; IMMUNOHISTOCHEMISTRY; METABOLISM; NUDE MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; ARGONAUTE PROTEINS; BRAIN; BRAIN NEOPLASMS; CARCINOGENESIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLIOBLASTOMA; GTP PHOSPHOHYDROLASES; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PROTEINS; MICE; MICE, NUDE; MICRORNAS; NEOPLASTIC STEM CELLS; REAL-TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, LONG NONCODING; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84991769635     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.28568     Document Type: Erratum

References (49)

1. Thorne AH, Meisen WH, Russell L, Yoo JY, Bolyard CM, Lathia JD, Rich J, Puduvalli VK, Mao H, Yu J, Caligiuri MA, Tridandapani S and Kaur B. Role of cysteine-rich 61 protein (CCN1) in macrophagemediated oncolytic herpes simplex virus clearance. Mol Ther. 2014; 22:1678-1687.
2. Visvader JE and Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell stem cell. 2012; 10:717-728.
3. Spina R, Voss DM, Asnaghi L, Sloan A and Bar EE. Atracurium Besylate and other neuromuscular blocking agents promote astroglial differentiation and deplete glioblastoma stem cells. Oncotarget. 2016; 7:459-472. doi: 10.18632/oncotarget.6314.
4. Liz J and Esteller M. lncRNAs and microRNAs with a role in cancer development. Biochimica et biophysica acta. 2016; 1859:169-176.
5. Wang JY, Liu XF, Wu HC, Ni PH, Gu ZD, Qiao YX, Chen N, Sun FY and Fan QS. CREB up-regulates long noncoding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res. 2010; 38:5366-5383.
6. Zhao X, Wang P, Liu J, Zheng J, Liu Y, Chen J and Xue Y. Gas5 Exerts Tumor-suppressive Functions in Human Glioma Cells by Targeting miR-222. Mol Ther. 2015.
7. Clemson CM, Hutchinson JN, Sara SA, Ensminger AW, Fox AH, Chess A and Lawrence JB. An architectural role for a nuclear noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles. Molecular cell. 2009; 33:717-726.
8. Hutchinson JN, Ensminger AW, Clemson CM, Lynch CR, Lawrence JB and Chess A. A screen for nuclear transcripts identifies two linked noncoding RNAs associated with SC35 splicing domains. BMC genomics. 2007; 8:39.
9. Fox AH and Lamond AI. Paraspeckles. Cold Spring Harbor perspectives in biology. 2010; 2:a000687.
10. Zhen L, Yun-Hui L, Hong-Yu D, Jun M and Yi-Long Y. Long noncoding RNA NEAT1 promotes glioma pathogenesis by regulating miR-449b-5p/c-Met axis. Tumour biology. 2015.
11. Guo S, Chen W, Luo Y, Ren F, Zhong T, Rong M, Dang Y, Feng Z and Chen G. Clinical implication of long noncoding RNA NEAT1 expression in hepatocellular carcinoma patients. International journal of clinical and experimental pathology. 2015; 8:5395-5402.
12. Chakravarty D, Sboner A, Nair SS, Giannopoulou E, Li R, Hennig S, Mosquera JM, Pauwels J, Park K, Kossai M, MacDonald TY, Fontugne J, Erho N, et al. The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nature communications. 2014; 5:5383.
13. Kim YS, Hwan JD, Bae S, Bae DH and Shick WA. Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma. BMC cancer. 2010; 10:576.
14. Frixa T, Donzelli S and Blandino G. Oncogenic MicroRNAs: Key Players in Malignant Transformation. Cancers. 2015; 7:2466-2485.
15. Wang P, Liu YH, Yao YL, Li Z, Li ZQ, Ma J and Xue YX. Long non-coding RNA CASC2 suppresses malignancy in human gliomas by miR-21. Cellular signalling. 2015; 27:275-282.
16. Roush S and Slack FJ. The let-7 family of microRNAs. Trends in cell biology. 2008; 18:505-516.
17. Boyerinas B, Park SM, Hau A, Murmann AE and Peter ME. The role of let-7 in cell differentiation and cancer. Endocrine-related cancer. 2010; 17:F19-36.
18. Zhang YK, Zhu WY, He JY, Chen DD, Huang YY, Le HB and Liu XG. miRNAs expression profiling to distinguish lung squamous-cell carcinoma from adenocarcinoma subtypes. Journal of cancer research and clinical oncology. 2012; 138:1641-1650.
19. Wang Y, Hu X, Greshock J, Shen L, Yang X, Shao Z, Liang S, Tanyi JL, Sood AK and Zhang L. Genomic DNA copynumber alterations of the let-7 family in human cancers. PloS one. 2012; 7:e44399.
20. Kong L, Du X, Hu N, Li W, Wang W, Wei S, Zhuang H, Li X and Li C. Downregulation of let-7e-5p contributes to endothelial progenitor cell dysfunction in deep vein thrombosis via targeting FASLG. Thrombosis research. 2016; 138:30-36.
21. Ventayol M, Vinas JL, Sola A, Jung M, Brune B, Pi F, Mastora C and Hotter G. miRNA let-7e targeting MMP9 is involved in adipose-derived stem cell differentiation toward epithelia. Cell death & disease. 2014; 5:e1048.
22. Zhang F and Cheong JK. The renewed battle against RASmutant cancers. Cellular and molecular life sciences. 2016.
23. Wang T, Li C, Xia C, Dong Y, Yang D, Geng Y, Cai J, Zhang J, Zhang X and Wang J. Oncogenic NRAS hyperactivates multiple pathways in human cord blood stem/progenitor cells and promotes myelomonocytic proliferation in vivo. American journal of translational research. 2015; 7:1963-1973.
24. Zhang J, Zheng J, Yang Y, Lu J, Gao J, Lu T, Sun J, Jiang H, Zhu Y, Zheng Y, Liang Z and Liu T. Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases. Scientific reports. 2015; 5:18678.
25. Saldanha G, Potter L, Lee YS, Watson S, Shendge P and Pringle JH. MicroRNA-21 expression and its pathogenetic significance in cutaneous melanoma. Melanoma research. 2016; 26:21-28.
26. You J, Zhang Y, Liu B, Li Y, Fang N, Zu L, Li X and Zhou Q. MicroRNA-449a inhibits cell growth in lung cancer and regulates long noncoding RNA nuclear enriched abundant transcript 1. Indian journal of cancer. 2014; 51:e77-81.
27. Wang P, Wu T, Zhou H, Jin Q, He G, Yu H, Xuan L, Wang X, Tian L, Sun Y, Liu M and Qu L. Long noncoding RNA NEAT1 promotes laryngeal squamous cell cancer through regulating miR-107/CDK6 pathway. Journal of experimental & clinical cancer research. 2016; 35:22.
28. Zhu WY, Luo B, An JY, He JY, Chen DD, Xu LY, Huang YY, Liu XG, Le HB and Zhang YK. Differential expression of miR-125a-5p and let-7e predicts the progression and prognosis of non-small cell lung cancer. Cancer investigation. 2014; 32:394-401.
29. Liu SS, Wang YS, Sun YF, Miao LX, Wang J, Li YS, Liu HY and Liu QL. Plasma microRNA-320, microRNA-let-7e and microRNA-21 as novel potential biomarkers for the detection of retinoblastoma. Biomedical reports. 2014; 2:424-428.
30. Cai J, Yang C, Yang Q, Ding H, Jia J, Guo J, Wang J and Wang Z. Deregulation of let-7e in epithelial ovarian cancer promotes the development of resistance to cisplatin. Oncogenesis. 2013; 2:e75.
31. Zhou M, Wang X, Shi H, Cheng L, Wang Z, Zhao H, Yang L and Sun J. Characterization of long non-coding RNAassociated ceRNA network to reveal potential prognostic lncRNA biomarkers in human ovarian cancer. Oncotarget. 2016; 7:12598-611. doi: 10.18632/oncotarget.7181.
32. Yao Y, Ma J, Xue Y, Wang P, Li Z, Liu J, Chen L, Xi Z, Teng H, Wang Z, Li Z and Liu Y. Knockdown of long noncoding RNA XIST exerts tumor-suppressive functions in human glioblastoma stem cells by up-regulating miR-152. Cancer Lett. 2015; 359:75-86.
33. Chiyomaru T, Fukuhara S, Saini S, Majid S, Deng G, Shahryari V, Chang I, Tanaka Y, Enokida H, Nakagawa M, Dahiya R and Yamamura S. Long non-coding RNA HOTAIR is targeted and regulated by miR-141 in human cancer cells. J Biol Chem. 2014; 289:12550-12565.
34. Zheng J, Li XD, Wang P, Liu XB, Xue YX, Hu Y, Li Z, Li ZQ, Wang ZH and Liu YH. CRNDE affects the malignant biological characteristics of human glioma stem cells by negatively regulating miR-186. Oncotarget. 2015; 6:25339-25355 doi: 10.18632/oncotarget.4509.
35. Gyorffy B and Schafer R. Biomarkers downstream of RAS: a search for robust transcriptional targets. Current cancer drug targets. 2010; 10:858-868.
36. Orouji E, Orouji A, Gaiser T, Larribere L, Gebhardt C and Utikal J. MAP kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma. International journal of cancer Journal international du cancer. 2016; 138:2257-2262.
37. Vieira GC, Chockalingam S, Melegh Z, Greenhough A, Malik S, Szemes M, Park JH, Kaidi A, Zhou L, Catchpoole D, Morgan R, Bates DO, Gabb PD and Malik K. LGR5 regulates pro-survival MEK/ERK and proliferative Wnt/beta-catenin signalling in neuroblastoma. Oncotarget. 2015; 6:40053-40067. doi: 10.18632/oncotarget.5548.
38. Bartholomeusz C and Gonzalez-Angulo AM. Targeting the PI3K signaling pathway in cancer therapy. Expert opinion on therapeutic targets. 2012; 16:121-130.
39. Park S, Chapuis N, Tamburini J, Bardet V, Cornillet-Lefebvre P, Willems L, Green A, Mayeux P, Lacombe C and Bouscary D. Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica. 2010; 95:819-828.
40. Paternot S and Roger PP. Combined inhibition of MEK and mammalian target of rapamycin abolishes phosphorylation of cyclin-dependent kinase 4 in glioblastoma cell lines and prevents their proliferation. Cancer research. 2009; 69:4577-4581.
41. Stuart DD and Sellers WR. Targeting RAF-MEK-ERK kinase-scaffold interactions in cancer. Nature medicine. 2013; 19:538-540.
42. Johnson DB and Puzanov I. Treatment of NRAS-mutant melanoma. Current treatment options in oncology. 2015; 16:15.
43. Hsu HC, Thiam TK, Lu YJ, Yeh CY, Tsai WS, You JF, Hung HY, Tsai CN, Hsu A, Chen HC, Chen SJ and Yang TS. Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients. Oncotarget. 2016; 7:22257-70. doi: 10.18632/oncotarget.8076.
44. Johnson DB, Lovly CM, Flavin M, Panageas KS, Ayers GD, Zhao Z, Iams WT, Colgan M, DeNoble S, Terry CR, Berry EG, Iafrate AJ, Sullivan RJ, Carvajal RD and Sosman JA. Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer immunology research. 2015; 3:288-295.
45. Pardo OE, Castellano L, Munro CE, Hu YL, Mauri F, Krell J, Lara R, Pinho FG, Choudhury T, Frampton AE, Pellegrino L, Pshezhetskiy D, Wang YL, Waxman J, Seckl MJ and Stebbing J. miR-515-5p controls cancer cell migration through MARK4 regulation. Embo Rep. 2016; 17:570-584.
46. Meng D, Yang S, Wan X, Zhang Y, Huang W, Zhao P, Li T, Wang L, Huang Y, Li T and Li Y. A transcriptional target of androgen receptor, miR-421 regulates proliferation and metabolism of prostate cancer cells. The international journal of biochemistry & cell biology. 2016; 73:30-40.
47. Zheng J, Liu X, Wang P, Xue Y, Ma J, Qu C and Liu Y. CRNDE promotes malignant progression of glioma by attenuating miR-384/PIWIL4/STAT3 axis. Mol Ther. 2016.
48. Yao Y, Ma J, Xue Y, Wang P, Li Z, Li Z, Hu Y, Shang X and Liu Y. MiR-449a exerts tumor-suppressive functions in human glioblastoma by targeting Myc-associated zincfinger protein. Molecular oncology. 2015; 9:640-656.
49. Ciceroni C, Bonelli M, Mastrantoni E, Niccolini C, Laurenza M, Larocca LM, Pallini R, Traficante A, Spinsanti P, Ricci-Vitiani L, Arcella A, De Maria R, Nicoletti F, Battaglia G and Melchiorri D. Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas. Cell death and differentiation. 2013; 20:396-407.